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INTRODUCTION
Bone marrow transplantation from an HLA-identical
sibling donor is effective therapy for patients with aplastic
anemia. A 3-year actuarial survival of 92% was reported for
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ABSTRACT
Allogeneic marrow transplantation offers curative therapy for patients with aplastic anemia. We analyzed retrospec-
tive results in 141 patients with severe aplastic anemia who received transplants between 1988 and 1995 from an
unrelated volunteer donor identified through the National Marrow Donor Program (NMDP). All patients had failed
one or more courses of immunosuppressive therapy. Of the patients, 121 (86%) received a radiation-containing con-
ditioning regimen, and 20 (14%) were given chemotherapy only. Based on serologic human leukocyte antigen (HLA)
typing (class I and II), 105 patients (74%) received HLA-matched marrow, and 36 (26%) received marrow mis-
matched for at least one HLA-A, -B, or -DR antigen. Allele-level (molecular) typing for HLA-DRB1 was available in
108 donor-recipient pairs; 77 patients received DRB1-matched and 31 DRB1-mismatched transplants. All but 13% of
patients were given a cyclosporine-containing regimen for graft-vs.-host disease (GVHD) prophylaxis, and 45
patients (32%) received marrow that was T cell–depleted. Among 131 evaluable patients, 116 (89%) achieved sus-
tained engraftment and 15 (11%) did not. Among patients with engraftment, acute GVHD of grades II–IV developed
in 60 patients (52%) and extensive chronic GVHD in 24 patients at risk (31%). Currently, 51 patients (36%) are sur-
viving at 11–94 months (median 36) after transplantation. All but five have Karnofsky scores ‡ 80. Patients who
received a serologically matched transplant fared somewhat better than did patients given a serologically mismatched
transplant (p = 0.03). Patients with donors matched by both serology and allele-level DRB1 typing had significantly
better survival than DRB1-mismatched patients with 56 vs. 15% surviving at 3 years (p = 0.001). Outcome in patients
transplanted within 3 years of diagnosis was superior to that among patients transplanted with greater delay. Major
causes of death were graft failure, GVHD, and infections. These data suggest that unrelated marrow transplantation
offers successful therapy for a proportion of patients who have failed immunosuppressive therapy. 
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39 patients conditioned with antithymocyte globulin (ATG)
and cyclophosphamide and transplanted with marrow from
an HLA-identical related donor [1]. A compatible family
donor is available for <30% of patients, however; therefore,
most patients receive nontransplant treatment, generally
immunosuppressive therapy, as a first-line approach [2–5].
Frickhofen et al. [3] described a 70% response rate and 64%
survival at 41 months in patients given ATG plus cyclo-
sporine. Bacigalupo et al. [4] reported an 82% response rate
and 92% survival at 34 months in 40 patients with aplastic
anemia in whom treatment with ATG, cyclosporine, gluco-
corticoids, and granulocyte colony-stimulating factor (G-
CSF) was initiated within 30 days of diagnosis. At other cen-
ters, however, response rates of 30–40%, either with single-
agent ATG or a combination of ATG and cyclosporine, and
actuarial 10-year survival in the range of 40% have been
observed [2,5,6]. Patients who are unresponsive to immuno-
suppressive therapy or who have recurrent marrow failure
after an initial response frequently are treated with repeated
courses of immunosuppression or hematopoietic growth
factors [7]. Patients who respond to immunosuppressive
therapy generally do not achieve normal hematopoiesis [8].
Furthermore, as many as 15–45% of these patients eventual-
ly develop paroxysmal nocturnal hemoglobinuria, myelodys-
plastic syndrome, or leukemia [1,9–12].
The feasibility of marrow transplantation from alterna-
tive donors (relatives who are less than completely HLA
matched or unrelated volunteer donors) has been explored.
Results with partially matched related donors have been
summarized in several recent publications [13–17]. Initial
results with unrelated donors identified through the Nation-
al Marrow Donor Program (NMDP) have been presented
by Gajewski and Chattopadhyay [18] and Kernan et al. [19].
Here, we retrospectively analyzed results in 141 patients
transplanted from unrelated donors recruited through the
NMDP.
MATERIALS AND METHODS
Patients
The study population consisted of 154 patients with
severe aplastic anemia (excluding patients with Fanconi’s
anemia) who received marrow transplants in the U.S.
between 19 February 1988 and 10 May 1995. Baseline or fol-
low-up reports were not available on 13 transplant recipients
because the respective centers failed to complete data forms.
Thus, data on 141 patients were available for analysis.
Patient and transplant characteristics are summarized in
Table 1. All patients had received one or several courses of
immunosuppressive therapy consisting of a single agent or
combination therapy (Table 2). The decision to proceed to
transplant was exclusively that of the transplant center. Thus,
the cohort under study includes patients who never showed
any improvement of hematopoietic parameters, patients who
did improve on immunosuppressive therapy and subsequent-
ly relapsed, and patients who had responded repeatedly to
immunosuppression but never achieved a sustained response.
Patients were transplanted at 36 transplant centers in the
U.S., each of which carried out between one and 24 trans-
plants. Three centers transplanted 24, 20, and 17 patients,
respectively, accounting for 43% of all transplants. 
Donor selection, collection of marrow, and processing
The selection of donors was based on HLA serotyping
performed for HLA-A and -B and a combination of serotyp-
ing and genotyping for HLA-DRB1 according to standard
procedures [20,21]. Donor characteristics are summarized in
Table 1. Patient, donor, and transplant characteristics
Characteristic Value
Patient age (years) 0.9–47 (median 17.7)
Patient sex (male/female) 82 (58%)/59 (42%)
Donor sex (male/female) 81 (57%)/60 (43%)
Donor age (years) 21–53 (median 36)
Donor-patient sex combination*
Female to female 26 (19%)
Female to male 33 (24%)
Male to female 33 (24%)
Male to male 48 (34%)
Disease duration (months) 3.3–162 (median 13) 
Etiology
Unknown/idiopathic 93/40 (66%/28%)
Hepatitis/viral 4 (3%)
PNH 2 (1%)
Other 2 (1%)
Blood cell count at transplant (3109/L)
Leukocytes 0–11.7 (median 0)
Platelets 0–84 (median 0)
Donor-patient CMV status†
Negative to negative 28 (24%)
Negative to positive 50 (42%)
Positive to negative 15 (13%)
Positive to positive 25 (21%)
Prior transfusions 141 (100%)
RBC‡
Yes 37
No 10
Platelets‡
Yes 40
No 7
Conditioning regimens
TBI 1 (1%)
TBI + chemotherapy 93 (66%)
TBI + LFI + chemotherapy 7 (5%)
LFI + chemotherapy 20 (14%)
Chemotherapy 20 (14%)
Marrow cell dose 3108/kg 0.03–13.6 (median 2.9)
GVHD prophylaxis§
Methotrexate + cyclosporine 36 (25%)
Methotrexate + cyclosporine + other 35 (25%)
Cyclosporine 17 (12%)
Cyclosporine + other 40 (28%)
Methotrexate + other 4 (3%)
Other 6 (4%)
Data missing 3 (2%)
T-cell depletion 45 (32%)
For information on HLA matching, see Table 3. LFI, localized field irradia-
tion; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cells;
CMV cytomegalovirus.
*Unknown in one case.
†Information incomplete on 26 transplants.
‡Detailed data available on the last 49 patients transplanted.
§Including 43 patients given T-cell depleted marrow.
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Table 1. A mismatch of one HLA-A or -B antigen was char-
acterized as minor if the mismatched antigen was in a cross-
reactive group (CREG) and as major if not. High-resolution
typing was performed retrospectively by several DNA-based
methods, predominantly by sequence-specific oligo-
nucleotide probes (SSOP) in 108 of 141 patients. 
Marrows were collected at 56 different collection cen-
ters, each harvesting marrow on one to 11 donors. Marrow
cells were harvested according to the policies of the NMDP
[22], placed in sterile plastic bags, and brought to the trans-
plant center by a courier.
Data collection
Data were collected in standardized forms provided by
the NMDP and included pretransplant information, peri-
transplant events, and short-term and long-term follow-up.
The median length of follow-up was 50 months (range
22–110). Data on survival are as of 1 March 1997.
Engraftment
The day of engraftment was defined as the first of 3
consecutive days on which the neutrophil count exceeded
500/mm3. Thus, patients who did not have a neutrophil
count of >500/mm3 for 3 consecutive days at any time after
transplantation were considered as having primary graft
failure. Patients with initial engraftment in whom a severely
hypocellular marrow or an absolute neutrophil count of
<500/mm3 recurred were considered to have secondary
graft failure if they survived for at least 21 days. Patients
who survived for <21 days were considered evaluable only if
they had proven engraftment or developed GVHD before
death.
GVHD
The stage of involvement of the skin, liver, and intesti-
nal tract by acute GVHD was determined according to
standard criteria [23,24]. An overall grade based on the sum
of the individual stages was reported: 0 was assigned for a
score of 0; I for scores of 1 to 2; II for scores of 3 to 4
(except in cases in which the skin, liver, or intestine alone
was considered to have a score of 4, in which case a grade of
III was assigned); and a grade of III–IV for scores of 5 or
more [19]. In a few cases [12], the overall grade reported by
physicians conflicted with the skin, liver, and gut involve-
ment reported. In those cases, the overall grade was
adjusted to be consistent with the organ-specific data.
Chronic GVHD was assessed as l imited (mild skin
involvement only) or extensive (skin, liver, and intestinal
tract involvement) [25].
Statistical analysis
Survival curves were estimated by the Kaplan-Meier
product limit method [26]. In univariate analyses, the log-
rank statistic [27] was determined. Cox proportional hazards
regression [28] was used to assess the impact of the follow-
ing factors on survival after transplant: recipient age, recipi-
ent cytomegalovirus (CMV) status, level of HLA matching
(a disparity of 0 or ‡ 1 antigen by serotyping), donor age,
donor-patient sex combination, T cell depletion, GVHD
prophylactic drugs, total-body irradiation (TBI), and the
interval between diagnosis and transplantation. Both uni-
variate and multivariate Cox regressions were done. All p
values reported are two sided.
Comparisons of proportions of patients engrafting were
based on x2 statistics. The occurrence of grade II–IV acute
GVHD was summarized using the cumulative incidence
estimator [27]. Cumulative incidence methodology is neces-
sary for this event because patients are subject to both ordi-
nary censoring and a competing risk (transplant-related
death).
RESULTS
Pretransplant therapy
All patients had received one or several cycles of
immunosuppressive therapy consisting of a single agent or
combinations of agents before transplantation. The actual
agents used for therapy were available only on the last 49
patients transplanted (since the information became manda-
tory in the NMDP report forms) (Table 2). These patients
received one to seven agents (median three); only three
patients had been treated with a single agent (ATG). The
interval from diagnosis to transplant was 3.3 to 162 months
(median 13). 
Identification of unrelated donors
Among the 141 patients, 105 (74%) received marrow
from a donor phenotypically matched for serologically
determined HLA-A, -B, and -DR antigens. The remaining
36 patients (26%) received a transplant from a donor who
was a minor or major mismatch for at least one HLA class
I (A or B) or class II (DR) antigen. Allele-level (molecular)
typing for DRB1 was available in 108 donor/recipient
pairs. Seventy-seven pairs, including 22 who were serologi-
cally mismatched for a class I antigen (minor in 12 and
major in 10), were matched for DRB1, and 31 (including
26 who were serologically matched) were mismatched for
DRB1 (Table 3). Thus, among the 108 pairs with molecu-
lar typing for DRB1, only 55 were matched for all antigens
tested. Twenty-two were mismatched for at least one and
three for at least two antigens.
The median time between initiation of the primary
search for a donor and marrow transplantation was 5
months (range 0.5–78). 
Table 2. Pretransplant therapy
Modality* No. patients
Any immunosuppression 141†
Glucocorticoids 40
ATG 41
Cyclosporine 40
Androgens 10
Growth factor‡ 13
*Given alone or in combinations.
†Specific information available only on the 49 most recently transplanted
patients. Per patient, one to seven (median three) agents were used.
‡Interleukin-3, granulocyte-macrophage colony-stimulating factor, granulo-
cyte colony-stimulating factor, stem cell factor.
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Outcome
Transplant outcome is summarized in Table 4.
Ten patients died before day 21 without evidence of
either engraftment or GVHD and were considered non-
evaluable. Among the 131 evaluable patients, 116 (89%)
achieved sustained engraftment at 9–71 days (median 18),
and 15 patients (11%) experienced graft failure. In 13
patients, graft failure was primary, whereas two patients had
transient evidence of engraftment but subsequently lost
their graft. Among 97 evaluable patients transplanted from a
serologically HLA-A, -B, -DR matched donor, 90 (93%)
engrafted compared with 26 of 34 (76%) transplanted from
a partially mismatched donor (p = 0.01). Among serological-
ly matched transplant recipients for whom DRB1 typing
was available, the incidence of graft failure was 6% with a
DRB1-matched donor, and 14% with a DRB1-mismatched
donor (p = 0.26).
Among 18 evaluable patients conditioned with a nonir-
radiation regimen, 16 (89%) engrafted compared with 100
of 113 (88%) conditioned with an irradiation-containing
regimen (p = 0.99). Engraftment and graft failure by radia-
tion dose are shown in Table 5. The incidence of graft fail-
ure was similar (10–16%) in patients who received cell doses
in the first three quartiles and appeared markedly lower
(3%) in patients receiving the highest cell doses
(>3.673108/kg; fourth quartile). However, this relationship
did not reach statistical significance (p = 0.23). Among
patients transplanted with unmanipulated marrow, 94%
achieved engraftment compared with 79% among those
transplanted with T cell–depleted marrow (p = 0.01).
The cumulative incidence of grade II–IV acute GVHD
among patients with sustained engraftment was 52% (Fig.
1). Among the 60 patients who developed GVHD requiring
therapy, 43 (37% of evaluable patients) had GVHD of grade
III–IV. The effects of conditioning regimen, marrow cell
dose, GVHD prophylaxis, and histocompatibility are sum-
marized in Table 5. The incidence of GVHD was highest in
patients who received the largest number of donor cells (p =
0.09). Among patients transplanted from a serologically
matched donor, those who were also matched at the allele
level for DRB1 had a cumulative incidence of acute GVHD
of 45% compared with 58% among patients transplanted
from a donor who was DRB1 nonidentical (p = 0.34). Exten-
sive chronic GVHD was reported in 24 of 77 patients (31%)
surviving 90 days or longer (in three patients the chronic
GVHD status was unknown).
At the time of last contact, 51 patients were surviving
and 90 had died. The Kaplan-Meier estimates of the proba-
bility of surviving are 0.40 (confidence interval [CI]
0.32–0.48) at 1 year, 0.37 (CI 0.29–0.45) at 2 years, and 0.34
(CI 0.26–0.43) at 5 years (Fig. 2). Importantly, donor/recipi-
ent match by allele-level typing had a striking impact on
survival (Fig. 3): patients given a transplant from a serologi-
cally matched donor who was also identical for DRB1 had a
survival probability of approximately 56% at 2–3 years,
compared with approximately 15% in patients transplanted
from a nonidentical donor. Patients transplanted within 3
years of diagnosis had a higher probability of survival than
patients transplanted later (Fig. 4) (see multivariable analy-
sis). Among patients ≤20 years of age who were transplanted
within 3 years of diagnosis from a donor who was matched
by serologic and DRB1 typing, the probability of survival
was 62%, and no deaths were observed after 1 year. 
The Karnofsky performance status of surviving patients
was 100 in 29 patients, 90 in 12 patients, 80 in five patients,
and <80 in five patients.
Causes of death are summarized in Table 6. Graft fail-
ure, GVHD, and associated complications (infection, hem-
orrhage) were the major causes. Individual organ toxicity
accounted for most of the remaining cases.
Cox regression analysis
Results of univariable and multivariable Cox regression
analyses are summarized in Table 7. In both analyses, dis-
ease duration and HLA compatibility as determined by
Table 3. Correlation of serological (HLA-A, -B, -DR) and allele-level (molecular; DRB1) typing
Serologic HLA typing
Match Mismatch
Molecular typing for DRB1* A + B + DR A B A + B DR Total number of donor/recipient pairs
n 105 16 15 1 4
DRB1 match 55 11† 11† — — 77
DRB1 mismatch 26 1 2 — 2 31
Not determined 24 4 2 1 2 33
*Available in 108 donor/recipient pairs.
†Among these, 12 pairs differed for cross-reactive (CREG) antigens, and 10 showed major antigen differences.
Table 4. Transplant outcome 
Event No. patients/total patients (%)
Engraftment* 116/131 (89%)
Graft failure* 15/131 (11%)
Primary failure 13
Secondary failure 2
GVHD
Acute (II–IV) 60/116 (52%)
Extensive chronic† 24/77 (31%)
Survival 51/141 (36%)
*Ten patients died without engraftment or GVHD before day 21 and were
considered non-evaluable.
†Among patients surviving to day 90.
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serology were significant factors for survival. The impact of
HLA matching was further emphasized by incorporating
DRB1 typing results; the relative risk (RR) of death of a
patient transplanted from a DRB1-mismatched compared
with an -A, -B, -DRB1 matched donor was 2.7 (p = 0.001).
The RR for the group of patients for whom DRB1 typing
data were not available was 1.5 (p = 0.25). The relevance of
allele-level typing for DRB1 was confirmed in a multivari-
able model controlling for patient and donor age, sex, CMV
status, disease duration, conditioning regimen, and GVHD
Table 5. Transplant variables and transplant outcomes
Graft failure Acute GVHD (grade II–IV)‡
Variable n Early deaths* Total (secondary) % No. patients Percent cumulative incidence
Conditioning regimen
No irradiation 20 2 2 (0) 11 9 57
Irradiation (cGy) 121
400–800 31 2 3 (1) 10 15 58
1200–1500 72 5 9 (0) 13 28 48
Unknown dose 18 1 1 (1) 6 8 50
Marrow cell dose (108/kg)
<1.65 35 3 5 (1) 16 12 44
1.65–2.87 36 2 5 (1) 16 10 37
2.88–3.67 35 5 3 (0) 10 15 56
>3.67 35 0 1 (0) 3 23 68
GVHD prophylaxis†
T-cell depletion 45 2 9 (1) 21 11 32
Other 95 8 5 (1) 6 49 60
Donor/patient HLA
Serologic match 105 8 7 (1) 7 47 52
Serologic mismatch 36 2 8 (1) 24 13 50
Allele-level DRB1typing§
Identical 55 3 3 (1) 6 22 45
Nonidentical 26 4 3 (1) 14 11 58
Not completed 24 1 1 (0) 4 14 64
*Patients who died before day 21.
†Unknown in one.
‡Among 116 patients with sustained engraftment.
§Among 105 serologically matched pairs.
Figure 1. Incidence of acute GVHD
Cumulative incidence of grade II–IV acute graft-vs.-host disease in patients transplanted from an unrelated donor who achieved sustained engraftment.
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prophylaxis: the RR for DRB1-mismatched vs. DRB1-
matched transplants was 3.3 (p = 0.001). No other statistical-
ly significant factors were identified, although the data sug-
gested that younger patients and patients transplanted from
younger donors fared better. Information on other potential
risk factors such as pretransplant immunosuppressive thera-
py and blood cell counts at transplantation was not suffi-
ciently complete to allow for meaningful analysis.
DISCUSSION
Bone marrow transplantation offers curative therapy for
severe aplastic anemia. With transplants from a genotypical-
ly HLA-matched sibling or phenotypically HLA-matched
relative, as many as 90% of patients become long-term sur-
vivors [1]. A suitably matched related donor is available for
less than one-third of otherwise eligible patients, however.
The decision to perform a transplant from an “alternative”
donor—an HLA-nonidentical relative [14–18] or an unre-
lated volunteer donor [29]—is difficult; although this proce-
dure clearly has curative potential, it also carries a consider-
able risk of morbidity and mortality. For these reasons and
because it takes on average at least 3 months from initiation
of an unrelated donor search to transplant, patients with
aplastic anemia who do not have an HLA-matched family
donor generally receive immunosuppressive therapy as first-
Figure 2. Overall survival
Probability of survival after transplantation from an unrelated donor after having failed immunosuppressive therapy. Tick marks indicate surviving patients.
Figure 3. HLA matching and survival
Probability of survival by human leukocyte antigen matching on the basis of serological typing and high-resolution typing for DRB1.
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line therapy [3–6]. Only if that approach fails are those
patients considered for transplantation. Because of the long
time from diagnosis to transplantation, patients generally
have received multiple transfusions and are broadly sensi-
tized and may suffer from iron overload. As a result of often
profound neutropenia of long duration, patients are fre-
quently infected [18,19,30]. They may also have been
exposed to hepatitis B and C or other viruses. The objective
of the present study was to assess the current status of unre-
lated transplantation for severe aplastic anemia, to identify
potential risk factors for outcome, and to improve the data-
base for the design of future studies.
As suggested by results in smaller cohorts of patients
reported by individual centers [15–17], the major problems
identified in the present analysis were failure of sustained
engraftment, GVHD, infections, and organ toxicity, all con-
tributing to lower survival than is seen with transplants from
HLA-identical sibling donors. It is important to emphasize,
however, that several parameters in the present population
are distinctly different from those in HLA-identical sibling
transplants. The disease duration in these unrelated trans-
plant recipients (median 391 days) was four times longer
than that among recipients of related transplants (median
about 90 days), and the time from diagnosis did affect sur-
vival in the present study, although a strikingly lower sur-
vival was observed only in patients who were >3 years from
diagnosis at the time of transplant. Exposure to transfusion
products during the pretransplant interval presumably
resulted in allosensitization and thereby increased the risk of
graft rejection [18,30]. Because all patients had been trans-
fused pretransplant, however, allosensitization per se could
not be analyzed as a risk factor for transplant outcome. 
The most significant risk factor recognized was HLA
disparity between donor and recipient. A mismatch at the
level of HLA serology significantly increased the risk of graft
failure and decreased the probability of long-term survival.
The difference in outcome was even more striking when
allele-level typing for DRB1 was considered, although
patient numbers were insufficient to show a significant
impact on graft failure. Nevertheless, a survival of 56% (63%
in a subset of patients younger than 20 years and transplant-
ed within 3 years of diagnosis) in heavily pretreated patients
given a transplant from an unrelated volunteer donor is
encouraging. These data on DRB1 matching and outcome
are in agreement with observations by Baxter-Lowe et al.
[31] and Petersdorf et al. [32], who showed an increased inci-
dence of acute GVHD and decreased probability of survival
in patients with various diagnoses transplanted from an unre-
lated donor molecularly mismatched for a class II allele.
Taken together, these data also suggest that young patients
with aplastic anemia for whom a molecularly HLA-matched
unrelated donor is identified should be considered for trans-
Figure 4. Effect of time from diagnosis on survival
Probability of survival by time interval from diagnosis to transplant.
Table 6. Causes of death
Causes Time posttransplant (days) No. patients
Graft failure 18–79 (50)* 9
Acute GVHD 12–138 (62) 13
Infections
Fungal 8–439 (39.5) 12
Viral 34–253 (86) 7
Other 42–513 (488) 3
Hemorrhage 3–504 (34.5) 12
Organ toxicity
Pulmonary† 16–288 (51) 9
Hepatic 23–86 (62) 3
Cardiac 1, 2 2
Renal 7, 1494 2
Chronic GVHD 143–223 (167) 4
Malignancy 125–210 (136) 3‡
Other 16–84 (43) 10
*Range (median).
†Includes five patients with acute respiratory distress syndrome (ARDS).
‡All three malignancies were posttransplant lymphoproliferative diseases.
H.J. Deeg et al.
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plantation earlier in their course than is currently practiced.
On the other hand, results in patients transplanted from a
serologically or allele-level mismatched donor are probably
not different from those in patients given supportive care
only [33,34]. Further advances in management are required
to improve results in these patients.
It is also important to note that only half of the patients
included in the present analysis received GVHD prophylax-
is with methotrexate plus cyclosporine, currently considered
the standard regimen [35]; the remainder had been given
single-agent prophylaxis, which is associated with a higher
incidence of GVHD [36]. The more general use of the
methotrexate plus cyclosporine combination or conceivably
a combination of methotrexate plus FK506 (tacrolimus),
which is under investigation in randomized trials in patients
undergoing transplantation from related and unrelated
donors [37], may reduce the incidence of GVHD. 
T cell depletion of donor marrow, explored by many
transplant teams as a means of preventing GVHD
[13,16,29], was associated with a lower incidence of acute
GVHD relative to patients given T cell–replete marrow (32
vs. 60%; p < 0.01) but also resulted in a higher incidence of
graft failure (21 vs. 6%; p = 0.01) and did not improve sur-
vival (RR = 0.9; p > 0.5). Nevertheless, this approach remains
attractive in patients with nonmalignant disorders in which
no beneficial byproduct of GVHD in the form of a graft-vs.-
tumor effect can be expected. The usual strategy to improve
the probability of engraftment has been to increase the
intensity of conditioning, often by incorporating irradiation
into the regimen. In the present study, 85% of patients were
prepared with an irradiation-containing regimen. Although
other reports suggest that irradiation is effective in enhanc-
ing engraftment [18,38,39], this notion is not supported by
the present analysis, in which four rejections occurred in 18
evaluable nonirradiated patients (11%) compared with 13
rejections in 113 evaluable patients (12%) given irradiation
in one form or another. This is of interest because dose
intensification (addition of irradiation) is associated with
increased toxicity and often transplant-related mortality and,
as a result, generally does not lead to improved survival [40].
Furthermore, intensive conditioning regimens are associated
with a higher incidence of GVHD [40,41]. Thus, the goal
must be to achieve engraftment, even of T cell–depleted
marrow, with less intensive regimens to reduce regimen-
related morbidity and mortality and thereby improve sur-
vival. On the basis of this rationale, an ongoing trial com-
bines cyclophosphamide, ATG, and low-dose (33200,
23200, or 13200 cGy) rather than conventional dose
Table 7. Cox regression results
Univariate Multivariate
Factor Relative risk (of death) p value Relative risk (of death) p value
Patient age
,20 years 1.0 1.0
#20 years 1.3 0.24 1.5 0.09
Donor age
,35 years 1.0 1.0
$35 years 1.4 0.11 1.4 0.14
Donor sex fi patient sex
Female fi female 1.0 1.0
Female fi male 1.4 1.3
Male fi female 1.0 1.5
Male fi male 0.9 0.40* 0.9 0.40*
Disease duration prior to BMT
#1.0 year 1.0 1.0
1.0 to 3.0 years 1.0 0.9
.3.0 years 2.0 0.02* 2.1 0.01*
Patient CMV status
Negative 1.0 1.0
Positive 0.9 0.65 1.0 0.87
Preparative regimen
Chemotherapy only 1.0 1.0
Regimen incorporating irradiation 1.0 0.91 0.9 0.88
GVHD prophylaxis
Cyclosporine + methotrexate 1.0 1.0
Other 0.9 0.52 1.2 0.46*
T-cell depletion
No 1.0 1.0
Yes 0.9 0.60 0.8 0.38
HLA matching†
Matched 1.0 1.0
Mismatched 1.7 0.03 2.0 0.006
*The p value is for a likelihood ratio test for significance of entire set of factor levels in the Cox model.
†By serologic typing.
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(63200 cGy) TBI. Preliminary results are encouraging in
regard to both engraftment and survival [39].
Results of the present analysis also show that patients
who achieve engraftment and survive the immediate post-
transplant period usually do well subsequently. The current
data suggest in particular that chronic GVHD may not be
more frequent in recipients of unrelated transplants than in
HLA-identical sibling transplantation [42]. Very few late
deaths from infection or chronic GVHD were observed.
These results are in agreement with reports from single-
institution trials [14–17]. It is also of note that although
three fatal posttransplant neoplasms occurred, no new
hematologic disorders, as seen after immunosuppressive
therapy [6,10,43], were observed.
Thus, the results of this analysis confirm that patients
with aplastic anemia can be transplanted successfully from
unrelated donors. Early morbidity and mortality are higher
and survival lower than among matched related transplant
recipients. Tolerance does develop eventually in these
patients, however, allowing the return to a productive life.
In particular, young patients with an HLA-matched donor
who are transplanted early after diagnosis have an excellent
prognosis. Further studies should be directed at selecting
patients for earlier transplants, reducing the incidence of
acute GVHD, and developing nontoxic regimens for
patients who do not have a fully matched donor.
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